Why BioCryst Pharmaceuticals Rose 8% on Thursday

Why BioCryst Pharmaceuticals Rose 8% on Thursday
·1 min read

Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) rose after the company's second-quarter earnings call. A stronger than expected performance from the company's shiny new sales force drove the biotech stock 8.7% higher as of 3:58 p.m EDT on Thursday. Last December, the FDA approved BioCryst Pharmaceuticals' first drug, an oral treatment for hereditary angioedema (HAE) called Orladeyo.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting